Marketing-authorisation holder · United States
Accord Hlthcare
15 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
15 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
15 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AMLODIPINE AND OLMESARTAN MEDOXOMIL10mg base; 20mg | 10mg base; 40mg | 10mg/20mg | 10mg/40mg | 5mg base; 20mg | 5mg base; 40mg | 5mg/20mg | 5mg/40mg · Tablet | Amlodipine, Olmesartan medoxomilo | United States | Marketed | 2011 |
| CAPECITABINE150mg | 500mg · Tablet | Capecitabine | United States | Marketed | 2013 |
| CARBIDOPA AND LEVODOPA25mg; 100mg | 50mg; 200mg · Tablet, extended release | Carbidopa, Levodopa | United States | Marketed | 1999 |
| CARMUSTINE300mg/vial | 50mg/vial · Powder | Carmustine | United States | Not marketed | 2022 |
| DODEX1mg/ml · Injectable | Vitamin b12 | United States | Not marketed | 1972 |
| DOXAZOSIN MESYLATE1mg base | 2mg base | 4mg base | 8mg base · Tablet | Doxazosin | United States | Marketed | 2000 |
| GEMCITABINE HYDROCHLORIDE1.5gm/15ml (100mg/ml) | 1gm/10ml (100mg/ml) | 200mg/2ml (100mg/ml) | 2gm/20ml (100mg/ml) · Solution | Gemcitabine | United States | Not marketed | 2017 |
| METHOTREXATE5gm/50ml (100mg/ml) · Solution | Methotrexate | United States | Not marketed | 2020 |
| METHOTREXATE SODIUM PRESERVATIVE FREE100mg base/4ml (eq 25mg base/ml) | 1gm base/40ml (eq 25mg base/ml) | 1gm base/vial | 200mg base/8ml (eq 25mg base/ml) | 250mg base/10ml (eq 25mg base/ml) | 50mg base/2ml (eq 25mg base/ml) · Injectable | Methotrexate | United States | Marketed | 1959 |
| OSELTAMIVIR PHOSPHATE30mg base | 45mg base | 75mg base · Capsule | Oseltamivir | United States | Marketed | 2016 |
| REGADENOSON0.4mg/5ml (0.08mg/ml) · Solution | Regadenoson | United States | Marketed | 2022 |
| TOPOTECAN HYDROCHLORIDE1mg base/ml (eq 1mg base/ml) | 4mg base/4ml (eq 1mg base/ml) · Solution | Topotecan | United States | Marketed | 2011 |
| TRIENTINE HYDROCHLORIDE250mg | 500mg · Capsule | Trientine | United States | Marketed | 2018 |
| NINTEDANIB100mg base | 150mg base · Capsule | Nintedanib | United States | tentative | 2020 |
| PALIPERIDONE PALMITATE117mg | 156mg | 39mg | 78mg · Injectable | Paliperidone | United States | tentative | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 15 | 13 | 2 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.